Business Context and Reporting Period
This Form 8-K Current Report was filed by Illumina, Inc. on May 3, 2001. The report details a corporate governance action taken by the Board of Directors to implement a shareholder rights plan (commonly known as a "poison pill").
Key Financial Metrics
The filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a new dividend distribution of preferred share purchase rights.
- Dividend Declaration: One preferred share purchase right for each outstanding share of common stock.
- Record Date: May 14, 2001.
- Exercise Price: $100.00 per unit (one unit consists of one one-thousandth of a share of Series A Junior Participating Preferred Stock).
- Expiration Date: May 14, 2011.
- Redemption Price: $0.01 per right (redeemable by the Board prior to the distribution date).
Material Changes
The primary material change is the adoption of a rights agreement designed to deter unsolicited takeover attempts. Key provisions include:
- Trigger Threshold: Rights become exercisable if a person or group acquires 15% or more of the outstanding common stock, or upon the announcement of a tender offer that would result in such ownership.
- Flip-In Provision: Upon triggering, holders of rights (excluding the acquirer) may purchase shares of Illumina common stock or Series A preferred stock with a market value of two times the exercise price ($200.00 value for a $100.00 price).
- Flip-Over Provision: If the company is acquired in a merger after the rights are triggered, holders may purchase shares of the acquiring company with a market value of two times the exercise price.
- Voting and Liquidation: Each unit of Series A preferred stock carries 1,000 votes and entitles the holder to 1,000 times the dividend or liquidation payment per share of common stock.
Guidance, Outlook, and Risks
Management Commentary: The Board of Directors stated that the rights plan is intended to protect shareholders from coercive or unfair takeover tactics. The rights are designed to cause substantial dilution to an acquirer attempting to gain control on terms not approved by the Board.
Risks and Contingencies:
- Anti-Takeover Effect: The plan may discourage potential acquirers from making offers, even those that could be beneficial to shareholders.
- Board Discretion: The Board retains the right to redeem the rights at $0.01 per right prior to the distribution date, effectively neutralizing the plan if a friendly transaction is approved.
- Amendments: The Board may amend the terms of the rights without shareholder consent prior to the distribution date.
Important Facts for Investor Verification
- Verify the exact number of outstanding common shares to calculate the total number of rights issued.
- Confirm the specific terms of the Series A Junior Participating Preferred Stock in the Certificate of Designation (Exhibit 3.3).
- Monitor for any public announcements of tender offers or acquisitions exceeding the 15% beneficial ownership threshold.
- Note that the rights are not exercisable until the "distribution date" (triggered by a 15% acquisition or tender offer).
- Review the Rights Agreement (Exhibit 4.3) for specific anti-dilution adjustment mechanisms.